LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy
September 24, 2024 02:00 ET
|
LIfT BioSciences
Proceeds will be used to advance the Company’s IMANs into clinical trialsRaise underpins strong pre-clinical data demonstrating dual mechanism of action of LIfT’s IMANS London, 24 September 2024–...
11x Secures $24 Million Series A Funding Led by Benchmark to Create the Future of Digital Work
September 16, 2024 12:00 ET
|
11X AI INC.
11x secures $24 million Series A funding led by Benchmark to create the future of digital work.
SOLASTA Bio Completes $14m Series A to Accelerate Nature-Inspired Crop Protection
September 11, 2024 04:51 ET
|
SOLASTA Bio Ltd.
SOLASTA Bio, a leading agri-biotech company specialising in the next generation of green insecticides, has completed an oversubscribed $14 million Series A
Radiance BioPharma sponsoring Investor Cruise Event 2024
August 29, 2024 15:30 ET
|
Radiance BioPharma
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Radiance Biopharma Inc., a biopharmaceutical company developing next generation Antibody Drug Conjugates and Bispecific Antibody Drug Conjugates announced...
S64 Announces Successful Close of Series A Funding Round with investments from HPS Investment Partners and Sumitomo Mitsui Trust Bank
July 29, 2024 03:55 ET
|
S64 Capital
LONDON, July 29, 2024 (GLOBE NEWSWIRE) -- S64, the global alternatives fintech and solutions partner to the wealth management industry, today announced the successful close of its Series A funding...
FUZE Technology Secures $11.5M in Series A Funding to Propel Global Expansion of IoT Hardware and Software
June 13, 2024 08:00 ET
|
FUZE Technology
FUZE Technology (“FUZE”) announces the close of the company's Series A funding round, securing $11.5 million. FUZE also announces adFUZE.
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
June 10, 2024 03:00 ET
|
Amber Therapeutics
US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI)By targeting the pudendal nerve, Amber-UI has the unique...
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
May 08, 2024 09:00 ET
|
Therini Bio, Inc.
THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration
Keiretsu Forum Sponsors Quix Labs at the Innovation Funders Showcase During Angel Capital Association's Annual Summit
April 24, 2024 07:08 ET
|
Keiretsu Forum Mid-Atlantic
Keiretsu Forum Mid-Atlantic, South-East, and Texas regions proudly announce their sponsorship of Quix Labs at the upcoming Innovation Funders Showcase.
Carbon removal firm Captura expands Series A funding to US$45.3M
April 11, 2024 03:01 ET
|
Captura Corporation
Captura has announced it has further expanded its Series A funding round leading to a total of US$45.3M.